Breaking News
Get 50% Off 0
😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingPro CLAIM SALE
Close

Blueprint Medicines Corp (2L9)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
106.1500 -1.7000    -1.58%
14:00:59 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  US09627Y1091 
S/N:  A14SDD
  • Volume: 34
  • Bid/Ask: 105.3000 / 106.9500
  • Day's Range: 106.1500 - 108.0000
Blueprint Medicines Corp 106.1500 -1.7000 -1.58%

Blueprint Medicines Corp Company Profile

 
Get an in-depth profile of Blueprint Medicines Corp, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

661

Equity Type

ORD

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address 45 Sidney Street
Cambridge, 02139
United States
Phone 617 374 7580
Fax -

Top Executives

Name Age Since Title
Alexis A. Borisy 51 2011 Co-Founder & Director
Jeffrey W. Albers 52 2014 Chairman
Kathryn Haviland 47 2016 President, CEO & Director
Charles L. Sawyers 64 - Member of Scientific Advisory Board
Brian J. Druker 68 - Member of Scientific Advisory Board
William C. Hahn - - Member of Scientific Advisory Board
Nicholas B. Lydon 67 2011 Member of Scientific Advisory Board & Independent Director
Mark A. Goldberg 70 2015 Independent Director
George Daniel Demetri 67 2012 Chair of Scientific Advisory Board
Lonnel Coats 59 2016 Independent Director
Scott W. Lowe - - Member of Scientific Advisory Board
Habib Joseph Dable 55 2022 Independent Director
Daniella Beckman 45 2021 Independent Director
Lynn Seely 65 2016 Lead Independent Director
John Tsai 57 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BPMC Comments

Write your thoughts about Blueprint Medicines Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Alejandro Pe
Alejandro Pe Jun 16, 2021 4:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
There we go. Not big profit but a profit in a red day for the industry.
Alejandro Pe
Alejandro Pe Jun 15, 2021 10:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Anyone loading for tomorrow? I am.
Ronen xyz
Ronen xyz Jun 12, 2021 11:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bought on the dip, fda going to spike the price
Ronen xyz
Ronen xyz Jun 12, 2021 11:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
where is the spike ?
Alejandro Pe
Alejandro Pe Jun 10, 2021 5:16PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00247-3/fulltext
Alejandro Pe
Alejandro Pe Jun 09, 2021 9:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
PDUFA date coming up
Juan Carlos Gutierrez
Juan Carlos Gutierrez Jul 14, 2020 3:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
the average target price is 93.5 and the high target price is 122 why is nobody buying?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email